| Document |
Document Title |
|
WO/2015/022831A1 |
[Problem] To provide: a composition for promoting estrogen secretion and that is able to promote estrogen secretion; an estrogen secretion aromatic composition; and an estrogen aromatic tool. [Solution] The composition that is for promot...
|
|
WO/2015/022830A1 |
[Problem] To provide: a composition that is for promoting estrogen secretion and that can promote the secretion of estrogen; an estrogen secretion aromatic composition; and an estrogen aroma tool. [Solution] By means of a method mediated...
|
|
WO/2015/023601A1 |
This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.
|
|
WO/2015/022297A1 |
The new strain Lactobacillus pentosus CECT 7504 is provided. The strain presents as key advantages: a high survival to the antimicrobial factors found in vaginal fluid, factors that are often increased in a subset of patients with candid...
|
|
WO/2015/019311A1 |
The present invention relates to the acceleration of the start of growth of the quiescent follicles and/or to slowing down the depletion of the ovarian reserve by using a peptide having dual somatostatin antagonist/agonist activity, in o...
|
|
WO/2015/018421A1 |
The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG.In particular, the present invention relates to an antibody or antigen bindin...
|
|
WO/2015/018356A1 |
The present invention discloses a diarylhydantoin derivative, and preparation method, pharmaceutical composition, and application thereof. The present invention provides a diarylhydantoin derivative as represented by formula I, a pharmac...
|
|
WO/2015/014256A1 |
Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are p...
|
|
WO/2015/011977A1 |
Provided is a subcutaneous injection preparation that can induce superovulation in a cow by only one administration and, therefore is useful for producing good calves, said subcutaneous injection preparation containing an aluminum hydrox...
|
|
WO/2015/012194A1 |
The present invention addresses the problem of newly finding a compound that has no effect other than an effect of increasing cavernous pressure, different from conventional medicinal compositions for treating or ameliorating erectile dy...
|
|
WO/2015/007606A1 |
Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or proph...
|
|
WO/2015/005816A1 |
The invention relates to the field of veterinary science. A preparation for treating and preventing bovine postpartum endometritis containing the following components, by mass percentage: dioxidine 0.25-3.0; gentamicin sulfate 0.5-3.2...
|
|
WO/2015/005301A1 |
The purpose of the present invention is to provide a material from which stabilized PGF2α can be easily obtained and which is not only useful for medical purposes but also easily and commonly applicable to fish culture feeds, livestock ...
|
|
WO/2015/002391A1 |
The present specification relates to a composition which contains ginseng berry extract as an active ingredient. Further, the present specification relates to a composition which contains ginseng berry extract and alleviates premenstrual...
|
|
WO/2014/012805A9 |
A composition comprising i) oligomeric lactic acid with the following formula (I) wherein n is an integer from 2 to 20, from 2 to 19, or from 2 to 18, and wherein from about 10 to about 20% w/w of the total weight of the oligomeric lacti...
|
|
WO/2014/209980A1 |
The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
|
|
WO/2014/210425A1 |
N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-
pyrrolo[2,3- c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatme...
|
|
WO/2014/206345A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compos...
|
|
WO/2014/200234A1 |
The present invention relates to a composition and functional health food containing a composite extract of Rehmannia glutinosa and Pueraria lobata for preventing or treating menopausal symptoms; and a method for preventing or treating m...
|
|
WO/2014/199933A1 |
This invention relates to a bicyclic nitrogen-containing aromatic heterocyclic amide compound of formula (I), or a salt thereof, which has excellent Complex 1 inhibitory effect and AMPK activating effect, and which is useful as a therape...
|
|
WO/2014/199315A1 |
The present invention relates to novel derivatives of hydrophilic bioactive peptides which have been modified by introducing a lipophilic substituent through esterification of the free carboxylic group(s) of the peptide with an aliphatic...
|
|
WO/2014/197820A1 |
Compositions and methods are described herein for the treatment of cystic diseases using PPARγ modulators. In particular, compositions and methods are described herein for the treatment of cystic diseases using low doses of PPARγ modul...
|
|
WO/2014/197896A1 |
Disclosed are recombinant bacteriophage constructs and related heterologous peptide sequences for generating anti-GnRH immune responses in animals. The disclosed recombinant phage constructs and heterologous peptides, bind to antibodies ...
|
|
WO/2014/195413A1 |
The present invention relates to compositions and methods for controlling infections in non-human mammals, particularly intra-mammary infections (IMIs). The invention is particularly suited to control infections and enhance the welfare o...
|
|
WO/2014/195479A1 |
The present invention relates to a method for preparing a dry preparation of Alpinia galanga or Alpinia conchigera with high content of 1'S-1'-acetoxychavicol acetate and low microbiological count. Also provided is the use of such a dry ...
|
|
WO/2014/195469A1 |
The present invention relates to a composition comprising a dry preparation of Alpinia galanga (L.) Willd (Zingiberaceae) or Alpinia conchigera Griff. and a plant extract comprising compounds with anti-oxidative activity, such as an extr...
|
|
WO/2014/194975A1 |
The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-eth
yl-1-(pyrimidin-5-yl)-1 H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, ...
|
|
WO/2014/186843A1 |
Provided herein are methods and compositions for the targeted delivery to myometrial tissue of one or more agents capable of regulating contractility of myometrial tissue, wherein the one or more agents are contained or encapsulated with...
|
|
WO/2014/187744A1 |
The invention relates to a pharmaceutical composition for an on-demand non-hormonal contraception and to a method for producing said pharmaceutical composition. The composition contains 2H-indazoles as novel EP2 receptor antagonists in c...
|
|
WO/2014/184643A1 |
The present invention relates to a composition comprising lactic bacteria for topical vaginal use. The composition of the present invention is effectively applicable in the preventive and/or curative treatment of vaginal infections cause...
|
|
WO/2014/185516A1 |
The present invention pertains to a substance or method for preventing or treating mastitis in ruminant animals, particularly in dairy cows. Specifically provided are: a ruminant-animal-mastitis preventive or therapeutic agent characteri...
|
|
WO/2014/183175A1 |
The present invention refers to methods for production and/or purification of hormones, particularly follicle stimulating hormone (FSH), from human or animal origin, using a human cells platform, as well as products thus obtained and the...
|
|
WO/2014/183314A1 |
The present invention relates to an application of povidone iodine in preparation of a medicament for treating premature ejaculation. The medicament is a composition formed by the povidone iodine and any other biological adaptive vector,...
|
|
WO/2014/185542A1 |
Provided is a pharmaceutical composition in which an action of a compound represented by a general formula (1) is enhanced, and which is effective for pneumonia and vaginitis. Disclosed is a pharmaceutical composition for vaginitis or pn...
|
|
WO/2014/185601A1 |
The present invention relates to a pharmaceutical composition for preventing or treating menopausal symptoms, the composition containing Toxicodendron vernicifluum extract, or a flavonoid compound derived therefrom or a pharmaceutically ...
|
|
WO/2014/182044A1 |
The present invention relates to a composition for, inter alia, preventing menopausal disease comprising a soybean extract comprising coumestrol as an active ingredient, and more specifically relates to a composition for, inter alia, pre...
|
|
WO/2014/180565A1 |
The present invention relates to new synergistic associations of hyaluronic acid sodium salt (HANa), verbascoside (VB) and glycero-phospho-inositol (GPI), and the use of said associations in therapy, in particular in the topical treatmen...
|
|
WO/2014/179095A1 |
The present invention relates to methods of decreasing sperm production in a male mammal by administering an effective amount of SHP2 inhibitor to decrease the spermatogonial stem cell (SSC) population. In particular non-limiting embodim...
|
|
WO/2014/178448A1 |
The present invention relates to a composition including an Angelica gigas Nakai extract and Epimedium Koreanum extract for preventing or remedying male infertility, which is a combination of compositions effective for male infertility t...
|
|
WO/2014/175303A1 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
WO/2014/175757A1 |
The invention relates to veterinary science, in particular, to antiseptic formulations with a broad spectrum of activity, and concerns a drug for treating wound surfaces, inflamed mucosa, and postoperative sutures. The invention can be u...
|
|
WO/2014/175302A1 |
Provided are a new form of levonorgestrel, which is useful as an emergency contraception, etc., a solid dispersion of levonorgestrel, a manufacturing method for the same, and a drug composition. The differential scanning calorimetry sp...
|
|
WO/2014/175304A1 |
Provided are a new crystalline form of levonorgestrel, which is useful as an emergency contraception, etc., a manufacturing method for the same, and a drug composition. The powder X-ray diffraction spectrum of this β crystalline polym...
|
|
WO/2014/169395A1 |
Described herein is an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Three compounds with estradiol inhibitory capability (letrozole, anastrozole ...
|
|
WO/2014/170648A1 |
A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
|
|
WO/2014/169816A1 |
A long acting goserelin sustained release microsphere composition. The microsphere comprises goserelin, at least a lactide/glycolide copolymer, and poloxamer or polyethylene glycol. The sustained release microsphere has a higher bioavail...
|
|
WO/2014/166317A1 |
An external-use medicament for cleaning and care of the ovaries, vagina and vulva, the medicinal raw materials consisting of propolis extract, zedoary oil, and mint leaf filtrate; on the basis of the different properties of each natural ...
|
|
WO/2014/166971A1 |
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11 β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(penta
fluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 t...
|
|
WO/2014/163402A1 |
The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient and, more specifically, to a composition which promotes the general psychological an...
|
|
WO/2014/163520A1 |
The invention relates to medicine and concerns a combined preparation for treating diseases of the rectum and female genitalia (erosion, colpitis, condylomas, cysts, endometriosis, myomas, fibroids, polyps of various localisation, les...
|
